Company intelligence / Profile preview

SmartPharm Therapeutics

Cambridge, Massachusetts, United Statessmartpharmtx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Developing a DNA-based neutralizing antibody that can be given as an intramuscular injection to block COVID-19 infection. Awarded a contract from DARPA for this development.

Therapeutic areas: Rare DiseasesInfectious Diseases
Modalities: DNA-based therapeuticsRNA-based therapeuticsGene-encoded therapeutics (GET)
Industry: Biotech

Drug pipeline

1 asset

STI-2020dna

Pre-clinical

Indications: COVID-19

Partnerships

Defense Advanced Research Projects Agency (DARPA)

Beyond the preview

Go deeper on SmartPharm Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SmartPharm Therapeutics.